Occurrence of tuberculous pleurisy associated with infliximab therapy / 대한내과학회지
Korean Journal of Medicine
;
: 421-424, 2004.
Artículo
en Coreano
| WPRIM
| ID: wpr-89513
ABSTRACT
Infliximab is a chimeric antibody against tumor necrosis factor-alpha and it can be used in the treatment of ankylosing spondylitis. Tumor necorosis factor-alpha is a potent proinflammatory cytokine and plays a key role in the host response against tuberculosis. Infliximab is known to be effective on active ankylosing spondylitis but it can also cause reactivation of latent tuberculosis. Physicians should screen patients for latent tuberculous infection or disease before prescribing the drug. We experienced a case of tuberculous pleurisy after taking infliximab in a patient suffering from ankylosing spondylitis. We present the case with a review of literature.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Espondilitis Anquilosante
/
Tuberculosis
/
Tuberculosis Pleural
/
Factor de Necrosis Tumoral alfa
/
Tuberculosis Latente
/
Infliximab
Límite:
Humanos
Idioma:
Coreano
Revista:
Korean Journal of Medicine
Año:
2004
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS